Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
Portfolio Pulse from
Sanofi's two combination vaccine candidates for influenza and COVID-19 have received Fast Track designation from the US FDA. These are the first non-mRNA combination vaccines, and ongoing phase 1/2 studies are evaluating their safety and immune response.
December 11, 2024 | 6:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi's combination vaccines for influenza and COVID-19 have been granted Fast Track designation by the US FDA, potentially accelerating their development and approval process.
The Fast Track designation by the FDA is significant as it can expedite the review process, potentially leading to quicker market entry. This is positive news for Sanofi, as it positions them ahead in the combination vaccine market for influenza and COVID-19.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100